Document:

EX-10.1

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
 Exhibit 10.1 
  

			
	Mallinckrodt	  	COVIDIEN

 May 31, 2013 
 Mr. Larry Hamel 
 Chief Development Officer AcelRx Pharmaceuticals Inc. 351 Galveston Drive
Redwood City, CA 94063 
 Dear Mr. Hamel, 
 Mallinckrodt LLC (“Mallinckrodt”) is pleased to offer the following agreement (“Agreement”) to AcelRx Pharmaceuticals, Inc. (“AcelRx”) for Sufentanil Citrate (code 0672)
(hereinafter referred to as ‘‘Product”) delivered during the four (4) year period beginning on January 1, 2013 and ending on December 31, 2016 (the “Initial Term”). This Agreement may be extended only by
written agreement of both Mallinckrodt and AcelRx (any extension, together with the Initial Term, shall be referred to as the “Term”). 
 For purposes hereof, any reference to “Contract Year” shall mean each consecutive twelve (12) month period during the term of this Agreement coincident with calendar years, the first such
Contract Year being the calendar year 2013. 
 Mallinckrodt agrees to supply and AcelRx agrees to purchase Product initially at the prices
listed below: 
  

							
	Product	 	Code	 	Contract Year Volume	 	Price per Gram
				
	Sufentanil Citrate	 	0672	 	[*]	 	[*]

 The prices above shall be firm through December 31, 2013. Effective January 1, 2014 for the balance of the new
Contract Year, and every subsequent January 1 for the balance of the Contract Year then commenced, the price for Product shall be adjusted to reflect any increases or decreases in the cost to Mallinckrodt of all raw materials, labor, utilities
and regulatory compliance costs associated directly with the manufacture and supply of such Product hereunder incurred during the immediately prior Contract Year, provided that the price of Product shall not increase or decrease by more than [*]
from the price in effect for such Product during the immediately previous Contract Year. By December 1, 2013, and on every subsequent December 1 during the Term of this Agreement, Mallinckrodt will notify AcelRx in writing of the adjusted
prices to be charged for Product for the following Contract Year. 
 Except as otherwise expressly stated in this Agreement, AcelRx agrees that
it will purchase during every Contract Year during the term of this Agreement at least eighty percent (80%) of its annual requirements for Product for delivery during such Contract Year, subject to Mallinckrodt’s ability to supply.
Mallinckrodt agrees that, except as specified in the paragraph below, it will supply all quantities of Product that are ordered by AcelRx by the delivery date specified in the applicable 

  
 1 

 
purchase order. If Mallinckrodt is unable to supply all quantities of Product meeting the specifications in Exhibit A and the other requirements of this Agreement by the delivery date specified
in orders placed by AcelRx hereunder, then Mallinckrodt shall provide AcelRx with prompt written notice of such inability. If Mallinckrodt is unable to supply all quantities of Product meeting the specifications in Exhibit A and the other
requirements of this Agreement within fifteen (15) days of the delivery date specified in orders placed by AcelRx hereunder on two (2) or more occasions during any Contract Year, AcelRx shall thereafter be relieved of its obligation under
this Agreement to purchase at least eighty percent (80%) of its annual requirements for Product from Mallinckrodt and may purchase unlimited quantities of Product from other suppliers. For clarity, purchases of Product will be deemed to occur
during the Contract Year in which such Product is to be delivered for purposes hereof, and thus any purchase orders for Product submitted by AcelRx at the price in effect for the first Contract Year and otherwise in accordance with the requirements
hereof, prior to the beginning of the first Contract Year shall be deemed to be purchased by AcelRx during the first Contract Year hereof. 

AcelRx agrees to supply Mallinckrodt, on a quarterly basis, and beginning on January 1, 2013 a rolling forecast of its requirements for Product
during the next twelve (12) months. The forecast for the first four months is considered to be firm and binding, such that AcelRx is obligated to order, and Mallinckrodt is obligated to supply, the quantities of Product contained in the first
four (4) months of each forecast. The forecast for the last eight (8) months of that period is non-binding and will be used by Mallinckrodt for production planning. If Mallinckrodt is unable to timely deliver a quantity of any Product
ordered by AcelRx, then AcelRx will be permitted to purchase the same quantity of that Product of like grade and quality from another supplier and such amount shall not be used in determining whether AcelRx has met its purchase obligations for that
Product for any given Contract Year (i.e., the quantity purchased by AcelRx from another supplier shall not be counted as part of AcelRx ‘s annual requirements of Product for such year). 
 Notwithstanding any other provision hereof, Mallinckrodt’s obligation to supply Product to AcelRx hereunder and AcelRx’s obligation to purchase such Product from Mallinckrodt hereunder is
subject, at any given time, to the availability of sufficient quota granted by the United States Drug Enforcement Administration (“DEA”). Mallinckrodt and AcelRx both agree that they shall at all times cooperate in good faith in the
exercise and use of their commercially reasonable efforts to ensure that there is sufficient quota available to allow both parties fully to perform their obligations hereunder. If Mallinckrodt has insufficient quota to satisfy AcelRx’s
requirements for any Product as well as its other customers, Mallinckrodt shall immediately notify AcelRx of same in writing and shall consult with AcelRx regarding AcelRx’s anticipated orders. Mallinckrodt shall allocate available Product
among all of its customers, including AcelRx, in as fair and equitable a manner as possible, giving due consideration to historical purchasing patterns, forecasts, and all other relevant commercial factors. 

Mallinckrodt shall provide written notice to AcelRx if it intends to terminate its manufacture of the Product, which notice shall be provided at least
eighteen (18) months prior to the date on which Mallinckrodt will cease manufacturing Product, provided that, Mallinckrodt covenants that it shall not cease manufacture of the Product for any reason within its reasonable control at any time
during the Term and thus such notice may not be provided by Mallinckrodt to AcelRx before July 1, 2015. 
 Promptly after entering into
this Agreement, the parties shall negotiate in good faith a quality agreement that will address quality issues regarding the manufacture and supply of Product hereunder (the “Quality Agreement”). In the event of any conflict or
inconsistency between the terms of this Agreement and the Quality Agreement, this Agreement shall prevail in every case. 

  
 2 

 All sales of Product will be in accordance with the following terms and conditions: 

 

	 	•	 	 payment for Products is due thirty (30) days from the date on which AcelRx receives an invoice. Mallinckrodt shall not issue an invoice for
Products prior to the date on which it has shipped such Products to AcelRx or AcelRx ‘s designee, 

  

	 	•	 	 delivery is DDP (Incoterms 2010) the delivery destination specified by AcelRx in the applicable order, freight prepaid and added to invoice for all
shipments of Product with a destination in the continental United States (freight terms for shipments outside of the United States will be agreed upon at a later date), and title to and risk of loss or damage to Products will transfer to AcelRx once
the Products have been delivered to the delivery destination, and 

  

	 	•	 	 all Products will be ordered with at least one hundred twenty (120) days advance notice. 

Mallinckrodt represents and warrants, with respect to all Product supplied to AcelRx hereunder, that: 

 

	 	•	 	 Products will be manufactured by Mallinckrodt in accordance with the terms of the quality agreement to be entered into by the parties promptly after
the execution of this Agreement (the “Quality Agreement”), all applicable laws and regulations and current Good Manufacturing Practices as determined by the United States Food and Drug Administration (‘‘FDA”) using the
manufacturing process described in Mallinckrodt’s Drug Master File (“DMF”), and 

  

	 	•	 	 Products will meet the specifications attached as Exhibit A, as well as any other specifications mutually agreed to in writing by Mallinckrodt and
AcelRx. 

 AcelRx shall have the right, in accordance with the procedures specified in this paragraph, to reject any volume of
any Product supplied to it hereunder if any such Product fails to meet the specifications attached hereto as Exhibit A. AcelRx or its designee may inspect Product received by it from Mallinckrodt and if, within sixty (60) days of the date of
receipt of such Product, AcelRx has not given written notice to Mallinckrodt rejecting any such Product (which notice will provide a detailed description of the reason for such rejection), such Product will be deemed to have been accepted for all
purposes hereof. Notwithstanding the foregoing, if at any time after initial acceptance as provided in the above paragraph, AcelRx discovers that Products supplied by Mallinckrodt do not meet the applicable specifications and all other applicable
requirements of this Agreement, and the nature of such defect could not have been reasonably have been discovered or suspected by AcelRx from a review of the documents regarding such Products provided to it by Mallinckrodt with the shipment of the
applicable Products or from a visual inspection of the Products performed within sixty (60) days after delivery to the delivery destination, AcelRx may revoke its acceptance of such Products by providing written notice to Mallinckrodt of such
revocation. Such notice will identify in reasonable detail the nature of the defect and will be provided within thirty (30) days of the date on which AcelRx determines the existence of the defect. In the event AcelRx provides a timely rejection
notice or revocation of acceptance to Mallinckrodt with respect to any given volume of any Product and Mallinckrodt does not give written notice to AcelRx within twenty (20) days after its receipt of any such rejection or revocation notice that
it disagrees with AcelRx’s rejection or revocation of acceptance of such Product, any Product that is the subject of such rejection or revocation notice shall be deemed to have been rejected for all purposes hereof. If, however, within twenty
(20) days of its receipt of any rejection or revocation notice from AcelRx, Mallinckrodt, reasonably and in good faith, disagrees that any particular 

  
 3 

 
volume of any Product was properly rejected or that acceptance of such Product was properly revoked by AcelRx, Mallinckrodt shall provide notice of such disagreement to AcelRx setting forth the
reasons for its disagreement. If, within a reasonable period of time after the date of any notice of disagreement given by Mallinckrodt (not, in any event, to exceed thirty (30) days) the parties are unable to resolve any dispute relative to
the rejection of any particular volume of any Product, the matter will be referred to an independent third party expert acceptable to both parties whose decision as to whether or not any such Product was properly rejected or acceptance of such
Product was properly revoked shall be final and binding on the parties. If the independent third party expert determines that the Product in question was not properly rejected or acceptance of such Product was not properly revoked, then such Product
shall be deemed to have been accepted by AcelRx for all purposes hereof and the fees and expenses of such independent third party expert shall be paid by AcelRx. If the independent third party expert determines that the Product in question was
properly rejected or revoked or if the parties have previously agreed that such Product was properly rejected or revoked, then Mallinckrodt shall, at the option of AcelRx and as AcelRx’s sole remedies in the event of properly rejected or
revoked Product, either refund or credit AcelRx for any amounts payable hereunder for such Product or promptly replace the rejected Product or revoked Product with Product that meets applicable specifications and all other applicable requirements
hereof. Any properly rejected or properly revoked Product shall, at the option of Mallinckrodt, either be returned to Mallinckrodt or destroyed by AcelRx in an environmentally responsible manner, in either event at the sole cost and expense of
Mallinckrodt. 
 If Mallinckrodt intends to make any material changes in its production, testing or packaging procedures in the DMF documented
process for Product as required by FDA’s “Guidance for Industry to an approved NDA or ANDA” and Note for Guidance on the European Drug Master File procedure, CPMP/QWP/227/02, Mallinckrodt will notify AcelRx in writing and will provide
to AcelRx (in accordance with the pricing and other terms and conditions hereof) sufficient quantities of validation material of Product made using such changes in production, testing or packaging procedures (the “Modified Product”) at
least twelve (12) months (unless a lesser time to implement any change is dictated by law) before filling orders for Product placed by AcelRx with Modified Product. The parties acknowledge that the purpose of the immediately preceding sentence
is to allow AcelRx a reasonable amount of time to receive appropriate regulatory approval prior to Mallinckrodt implementing a significant change to its DMF. 
 All information that is provided by or on behalf of AcelRx to Mallinckrodt in connection with this Agreement including, without limitations, all quantities of Product forecasted or ordered by AcelRx and
all delivery dates and delivery destinations for such Product shall be AcelRx ‘s confidential information under the Non-Disclosure Agreement entered into by Mallinckrodt and AcelRx effective April 11, 2013 (the “Confidentiality
Agreement”). Similarly, all information that is disclosed to AcelRx by Mallinckrodt in connection this Agreement (except to the extent that it obtains AcelRx’s confidential information) and all information observed by AcelRx during any
inspection of Mallinckrodt’s manufacturing operations conducted in accordance with this Agreement will be deemed to be Mallinckrodt’ s confidential information under the Confidentiality Agreement. Each party acknowledges and agrees that
their obligations of confidentiality and restrictions on use with respect to the other party’s confidential information shall be governed by the terms of the Confidentiality Agreement. 
 AcelRx will have the right during normal business hours and upon advance arrangement with Mallinckrodt to inspect Mallinckrodt’s manufacturing operations to determine whether or not Mallinckrodt is
complying in all respects with its obligations hereunder. AcelRx warrants that all such inspection s and audits shall be carried out in a manner calculated not to unreasonably interfere with Mallinckrodt’s conduct of business and to insure the
continued confidentiality of Mallinckrodt’s business and technical information. Further, AcelRx agrees to comply with all of Mallinckrodt’s safety and security requirements during any visits to the Mallinckrodt facilities. 

  
 4 

 Mallinckrodt shall indemnify, defend and hold AcelRx, its affiliates and its and their respective directors,
officers, employees, agents, successors and assigns harmless from and against any damages, liabilities, costs and expenses (including, without limitation, reasonable attorneys’ fees) incurred in connection with any claims, suits or actions
brought by a third party (collectively, “Losses”) to the extent resulting from or alleged to result from (i) any breach of this Agreement by Mallinckrodt, or (ii) any negligence or willful misconduct of Mallinckrodt.
Notwithstanding the preceding sentence, in no event shall Mallinckrodt be liable to AcelRx for incidental, consequential, exemplary, special, punitive or any other similar type of damages whether or not Mallinckrodt has been advised of the
possibility of such damages and whether or not, in any particular set of circumstances, such damages are reasonably foreseeable. 
 Mallinckrodt
hereby disclaims the implied warranties of merchantability and fitness for a particular purpose and it is understood that the express warranties (if any) of Mallinckrodt set forth herein are in lieu of all other warranties, express or implied.

 AcelRx shall indemnify, defend and hold Mallinckrodt, its affiliates and its and their respective directors, officers, employees, agents,
successors and assigns (the “Mallinckrodt Indemnitees”) harmless from and against any Losses resulting from or alleged to result from: (i) the handling, storage, transportation, use, sale or marketing of any product containing any of
the Products supplied hereunder to AcelRx, (ii) any breach of this Agreement by AcelRx, or (iii) any negligence or willful misconduct of AcelRx, except to the extent any such Losses are attributable to Mallinckrodt’ s breach of its
obligations, representations or warranties under this Agreement or to any negligence or willful misconduct of Mallinckrodt. 
 Each party
‘s agreement to indemnify, defend, and hold harmless the other party and its respective indemnitees is conditioned upon: (a) the indemnified party providing written notice to the indemnifying party of any claim, demand, or action arising
out of the indemnified activities within thirty (30) days after the indemnified party has knowledge of such claim, demand or action, provided that any failure on the part of an indemnified party to notify the indemnifying party of receipt of
notice of a claim will relieve the notified party of its obligation to indemnify the notifying party for such claim under this Agreement only to the extent that the notified party has been prejudiced by the lack of timely and adequate notice,
(b) the indemnified party permitting the indemnifying party to assume full responsibility and authority to investigate, prepare for, settle and defend against any such claim, demand or action provided that, the indemnified party shall be
allowed to participate and intervene in any action at its own expense, (c) the indemnified party assisting the indemnifying party, at the indemnifying party’s reasonable expense, in the investigation of, preparation for and defense of any
such claim, demand or action, (d) the indemnified party not compromising or settling such claim, demand or action without the indemnifying party’s written consent, and (e) the indemnifying party not compromising or settling such
claim, demand or action (except for any such settlement or compromises that involves only the payment of money by the indemnifying party) without the indemnified party’s written consent. 
 No provision of any purchase order submitted by AcelRx or of any acknowledgment submitted by Mallinckrodt or of any other document submitted by either party shall be controlling to the extent it sets
forth any terms or conditions that are additional to, or in conflict or inconsistent with, the terms or conditions of this Agreement. This Agreement represents the entire understanding of the parties with respect to its subject matter and supersedes
any prior agreements, other than the Confidentiality 

  
 5 

 
Agreement, which shall remain in effect and apply to disclosures of confidential information made between the parties under this Agreement. This Agreement shall be governed by the laws of the
State of New York, without reference to its conflict of law principles that might apply the law of another jurisdiction. Those provisions that by their nature are intended to survive termination or expiration of this Agreement including, without
limitation, confidentiality and indemnity obligations, shall survive the termination or expiration of this Agreement for any reason. 

Mallinckrodt hereby represents and warrants that it is not using and it will not use the services of any person or entity if such a person or entity is,
debarred by the FDA under the Generic Drug Enforcement Act of 1992. If, during the term of this Agreement, Mallinckrodt or any person or entity whose services are being used by Mallinckrodt is debarred by the FDA, Mallinckrodt will immediately
notify AcelRx of same. 
 Either party may terminate this Agreement upon written notice if the other party materially breaches this Agreement
and fails to cure the breach within thirty (30) days after receipt of written notice from the non-breaching party specifying the nature of such breach. 
 Mallinckrodt appreciates the opportunity to work with AcelRx in supplying the highest quality bulk narcotics products for AcelRx dosage product production. Please call your Mallinckrodt Sales
Representative, Nick Litzsinger, with any additional requests. 
 Mallinckrodt LLC 

 
 

 

  
 6 

 Exhibit A 
 Mallinckrodt Specification for Sufentanil Citrate Code 0672 
  

					
	TESTS	  	LIMITS	  	
	Appearance	  	White to almost white powder	  	
			
	Identification A (IR) (USP) (EP)	  	Matches standard	  	
			
	Identification B (lN) (USP)	  	Matches standard	  	
			
	Identification C (Citrate) (USP)	  	Light Red Color	  	
			
	Identification D (Major peak)(USP)	  	Retention matches	  	
			
	Loss on drying (USP) (EP)	  	0.50% max.	  	
			
	Heavy Metals (as Pb) (USP)	  	0.002% max.	  	
			
	Limit of Acetone (GC)(USP)	  	0.20.% max.	  	
			
	Assay (HPLC)(Dried Basis)(USP)	  		  	
	Sufentanil Citrate	  	98.0 - 101.0% w/w	  	
			
	Related Substances (HPLC)(equal to EP)	  		  	
	Step IV intermediate	  	0.15% max.	  	
	Step V intermediate (EP Impurity C)	  	0.15% max.	  	
	Step VI intermediate(EP Impurity E)	  	0.15% max.	  	
	Unknown Related Substances (each)	  	0.10% max.	  	
	Total Related Substances	  	1.0% max.	  	
			
	Assay (Titration) (EP) (dried basis)	  	99.0 - 101.0% w/w	  	
			
	Appearance of Solution (EP)	  		  	
	 Degree of Clarity
	  	Clear	  	
	 Degree of Coloration
	  	Colorless	  	
			
	Related Substances (HPLC) (EP)	  		  	
	EP Impurity D	  	0.5% Area Max	  	
	EP Impurity F	  	0.5% Area Max	  	
	EP Impurity H	  	0.5% Area Max	  	
	Other Impurities (Each) Total	  	0.10% Area Max	  	
	Related Substances	  	1% Area Max	  	

  
 7EX-10.1

 Exhibit 10.1 

DIADEXUS, INC. 
 KEY
EMPLOYEE SEVERANCE BENEFIT PLAN 
 1. Introduction. This diaDexus, Inc. Key Employee Severance Benefit Plan (the
“Plan”) is established by diaDexus, Inc. (the “Company”) on October 30, 2013 (the “Effective Date”). The Plan provides for
severance benefits to selected employees of the Company. This document constitutes the Summary Plan Description for the Plan. 
 2. Definitions. For
purposes of the Plan, the following terms are defined as follows: 
 (a) “Base Salary” means the
Participant’s base salary in effect immediately prior to date of the Qualifying Termination, ignoring any reduction in base salary that forms the basis for Constructive Termination. 

(b) “Board” means the Board of Directors of the Company. 

(c) “Cause” means (i) the Participant’s willful failure to substantially perform the
Participant’s duties for the Company (other than any such failure resulting from the Participant’s total and permanent disability); (ii) the Participant’s willful failure to carry out, or comply with, in any material respect any
lawful directive of the Board; (iii) the Participant’s commission at any time of any act or omission that results in, or may reasonably be expected to result in, a conviction, plea of no contest, plea of nolo contendere or imposition of
unadjudicated probation for any felony or crime involving moral turpitude; (iv) the Participant’s unlawful use (including being under the influence) or possession of illegal drugs on the Company’s premises or while performing the
Participant’s duties and responsibilities for the Company; (v) the Participant’s commission at any time of any act of fraud, embezzlement, misappropriation, misconduct, conversion of assets of the Company or breach of fiduciary duty
against the Company (or any predecessor thereto or successor thereof); or (vi) the Participant’s material breach of any agreement with the Company (including, without limitation, any breach of the restrictive covenants of any such
agreement); and which, in the case of clauses (i), (ii) and (vi), continues beyond thirty (30) days after the Company has provided the Participant written notice of such failure or breach (to the extent that, in the reasonable judgment of
the Board, such failure or breach can be cured by the Participant). Whether or not an event giving rise to “Cause” occurs will be determined by the Board in its sole discretion. 

(d) “Change in Control” means (i) the acquisition of the Company by another entity, or entities
acting as a group, by means of any transaction or series of related transactions (including, without limitation, any reorganization, merger or consolidation) that results in such entity or entities holding more than fifty percent (50%) of the
outstanding voting power of the Company (other than a bona fide equity financing transaction or transfers between affiliated funds) or (ii) a sale or other disposition by the Company of all or substantially all of the assets of the Company, in
either case, only if such transaction is also a change in the ownership or effective control of the Company, or a change in the ownership of a substantial portion of the Company’s assets, as described in Treasury Regulation
Section 1.409A-3(i)(5). 

 (e) “Change in Control Termination” means (i) an
Involuntary Termination Without Cause, or (ii) a Constructive Termination, in either case that occurs immediately prior to, on or within twelve (12) months after a Change in Control. 

(f) “Code” means the Internal Revenue Code of 1986, as amended. 

(g) “Common Stock” means the common stock of the Company. 

(h) “Constructive Termination” means the Participant’s resignation from all positions he or she then holds with
the Company, resulting in a Separation from Service, because one of the following events or actions is undertaken without the Participant’s written consent: (i) a material diminution in the Participant’s authority, duties or
responsibilities as in effect as of immediately prior to a Change in Control; (ii) a material reduction in the Participant’s annual base salary as in effect as of immediately prior to a Change in Control (other than a reduction that
affects all senior executives of the Company to a similar degree), which the parties agree is a reduction of ten percent (10%) or more; (iii) a material adverse change in the geographic location of the principal offices at which the
Participant must perform the Participant’s services as of immediately prior to a Change in Control (which shall in no event include a relocation of the Participant’s principal office of less than sixty (60) miles from South San
Francisco, CA); or (iv) the successor entity or surviving corporation in the Change of Control refuses to materially assume and comply with the terms of this Agreement. An event or action will not give the Participant grounds for Constructive
Termination unless (A) the Participant gives the Company written notice within sixty (60) days after the initial existence of the event or action that the Participant intends to resign in a Constructive Termination due to such event or
action; (B) the event or action is not reasonably cured by the Company within thirty (30) days after the Company receives written notice from the Participant; and (C) the Participant’s Separation from Service occurs within thirty
(30) days after the end of the cure period. 
 (i) “ERISA” means the Employee Retirement Income Security Act of
1974, as amended. 
 (j) “Involuntary Termination Without Cause” means a Participant’s involuntary termination
of employment by the Company, resulting in a Separation from Service, for a reason other than death, disability or Cause. 
 (k)
“Participant” means each individual who is employed by the Company and has received and returned a signed Participation Notice. 

(l) “Participation Notice” means the latest notice delivered by the Company to a Participant informing such
Participant that he or she is eligible to participate in the Plan, in substantially the form attached hereto as Exhibit A. 
 (m)
“Plan Administrator” means the Board or any committee of the Board duly authorized to administer the Plan. The Plan Administrator may, but is not required to be, the Compensation Committee of the Board (the “Compensation
Committee”). The Board may at any time administer the Plan, in whole or in part, notwithstanding that the Board has previously appointed a committee to act as the Plan Administrator. 

  
 - 2 - 

 (n) “Qualifying Termination’’ means (i) an Involuntary
Termination Without Cause that does not occur immediately prior to, on or within twelve (12) months after a Change in Control, or (ii) a Change in Control Termination. 

(o) “Section 409A” means Section 409A of the Code and the regulations and other guidance thereunder and any state
law of similar effect. 
 (p) “Separation from Service” means a “separation from service” within the
meaning of Treasury Regulations Section 1.409A-1(h), without regard to any alternative definition thereunder. 
 (q)
“Severance Period” means the number of months of severance that the Participant is eligible to receive under this Plan, as set forth on the Participant’s Participation Notice. 

3. Eligibility for Benefits. 
 (a)
Eligibility; Exceptions to Benefits. Subject to the terms of the Plan, the Company will provide the benefits described in Section 4 to the affected Participant. A Participant will not receive benefits under the Plan (or will
receive reduced benefits under the Plan) in the following circumstances, as determined by the Plan Administrator, in its sole discretion: 

(i) The Participant’s employment is terminated by either the Company or the Participant for any reason other than a Qualifying
Termination. 
 (ii) The Participant has not entered into the Company’s standard form of Proprietary Information and Inventions
Assignment Agreement (the “Proprietary Information Agreement”). 
 (iii) The Participant has failed to execute and
allow to become effective the Release (as defined and described below) within sixty (60) days following the Participant’s Separation from Service. 

(iv) The Participant has failed to return all Company Property. For this purpose, “Company Property” means all paper
and electronic Company documents (and all copies thereof) created and/or received by the Participant during his or her period of employment with the Company and other Company materials and property that the Participant has in his or her possession
or control, including, without limitation, Company files, notes, drawings records, plans, forecasts, reports, studies, analyses, proposals, agreements, financial information, research and development information, sales and marketing information,
operational and personnel information, specifications, code, software, databases, computer-recorded information, tangible property and equipment (including, without limitation, leased vehicles, computers, computer equipment, software programs,
facsimile machines, mobile telephones, servers), credit and calling cards, entry cards, identification badges and keys, and any materials of any kind that contain or embody any proprietary or confidential information of the Company (and all
reproductions thereof, in whole or in part). As a condition to receiving benefits under the Plan, a Participant must not make or retain copies, reproductions or summaries of any such Company 

  
 - 3 - 

 
documents, materials or property. However, a Participant is not required to return his or her personal copies of documents evidencing the Participant’s hire, termination, compensation,
benefits and stock options and any other documentation received as a stockholder of the Company. 
 (b) Relation to Other Agreements
and/or Plans. By accepting participation in this Plan, the Participant irrevocably waives his or her rights to any severance benefits (including vesting acceleration) to which the Participant may be entitled pursuant to any offer letter,
employment agreement, severance agreement, equity award agreement or any other similar agreement with the Company, or any other Company benefit plan, that is in effect on the date he or she signs the Participation Notice, other than any acceleration
of vesting benefits on a change in control transaction as provided under the Company’s equity incentive plans. 
 (c) Termination of
Benefits. A Participant’s right to receive benefits under the Plan will terminate immediately if, at any time prior to or during the period for which the Participant is receiving benefits under the Plan, the Participant, without the prior
written approval of the Plan Administrator: 
 (i) willfully breaches a material provision of the Proprietary Information Agreement and/or
any obligations of confidentiality, non-solicitation, non-disparagement, no conflicts or non-competition set forth in the Participant’s employment agreement, offer letter or under applicable law; 

(ii) encourages or solicits any of the Company’s then current employees to leave the Company’s employ for any reason or interferes
in any other manner with employment relationships at the time existing between the Company and its then current employees; or 
 (iii)
induces any of the Company’s then current clients, customers, suppliers, vendors, distributors, licensors, licensees, or other third party to terminate their existing business relationship with the Company or interferes in any other adverse
manner with any existing business relationship between the Company and any then current client, customer, supplier, vendor, distributor, licensor, licensee, or other third party. 

4. Payments and Benefits. Except as may otherwise be provided in the Participant’s Participation Notice, in the event of a Qualifying
Termination, the Company will provide the payments and benefits described in this Section 4, subject to the terms of the Plan. 
 (a)
Cash Severance. The Company will make a lump sum payment of “Cash Severance” to the Participant in an amount equal to his or her Base Salary for the Participant’s Severance Period, in accordance with the chart
below. The Cash Severance will be paid in a lump sum on the sixtieth (60) day after the date of the Participant’s Separation from Service. 
  

					
	 Tier
	  	 Position Level
	 	 Severance Period

	 1
	  	Chief Executive Officer	 	12 months
	 2
	  	Senior Vice Presidents and above	 	6 months
	 3
	  	Selected Vice Presidents
 (as designated by the Plan Administrator)
	 	4 months

  
 - 4 - 

 (b) Health Insurance Premiums. If the Participant timely elects continued coverage under
the Consolidated Omnibus Budget Reconciliation Act of 1985 (together with any state law of similar effect, “COBRA”), the Company will pay the full amount of the Participant’s COBRA premiums, or will provide coverage
under the Company’s self-funded broad based health insurance plans, on behalf of the Participant, including coverage for the Participant’s eligible dependents, until the earliest of (i) the end of the number of months in the
Participant’s Severance Period, (ii) the expiration of the Participant’s eligibility for the continuation coverage under COBRA, or (iii) the date when the Participant becomes eligible for substantially equivalent health insurance
coverage in connection with new employment or self-employment (such period from the date of the Qualifying Termination through the earliest of (i) through (iii), the “COBRA Payment Period”). However, if at any time the
Company determines, in its sole discretion, that the payment of the COBRA premiums would result in a violation of the nondiscrimination rules of Section 105(h)(2) of the Code or any statute or regulation of similar effect (including, without
limitation, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of providing the COBRA premiums or credit under the self-funded plan, the Company will instead pay
the Participant, on the first day of each month of the remainder of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month (or, in the case of a self-funded plan, the monthly cost of such coverage), subject
to tax withholdings and deductions. On the sixtieth (60) day following the Participant’s Separation from Service, the Company will make the first payment under this paragraph equal to the aggregate amount of payments that the Company would
have paid through such date had such payments commenced on the Separation from Service through such sixtieth (60) day, with the balance of the payments paid thereafter on the original schedule. In all cases, if the Participant becomes eligible
for coverage under another employer’s group health plan or otherwise ceases to be eligible for COBRA during the COBRA Payment Period, the Participant must immediately notify the Company of such event, and all payments and obligations under
paragraph will cease. For purposes of this paragraph, any applicable insurance premiums that are paid by the Company will not include any amounts payable by the Participant under a Section 125 of the Code health care reimbursement plan, which
amounts, if any, are the sole responsibility of the Participant. 
 (c) Double Trigger Vesting. In the event of a Qualifying
Termination that is a Change in Control Termination, each of the Participant’s then outstanding and unvested compensatory equity awards will fully vest, and, as applicable, become exercisable, effective as of immediately prior to the Qualifying
Termination. 
 5. Additional Requirements. 

(a) Release. To be eligible to receive any benefits under the Plan, a Participant must sign a general waiver and release, in
substantially one of the forms attached hereto as Exhibit B, Exhibit C, or Exhibit D, as appropriate (the “Release”), and such Release must become effective in accordance with its terms, in each case
within sixty (60) days following the Qualifying Termination (the “Release Date”). The Plan Administrator, in its sole discretion, 

  
 - 5 - 

 
may modify the form of the required Release to comply with applicable law, and any such Release may be incorporated into a termination agreement or other agreement with the Participant. 

(b) Certain Reductions. The Plan Administrator will reduce a Participant’s benefits under the Plan by any other statutory
severance obligations or severance obligations (including pay in lieu of notice) payable to the Participant by the Company (or any successor thereto) that are due in connection with the Participant’s Qualifying Termination and that are in the
same form as the benefits provided under the Plan (e.g., salary replacement, health insurance coverage, equity award vesting credit). Without limitation, this reduction includes a reduction for any benefits required pursuant to (i) any
applicable legal requirement, including, without limitation, the Worker Adjustment and Retraining Notification Act (the “WARN Act”), (ii) any Company policy or practice providing for the Participant to remain on the
payroll for a limited period of time after being given notice of the termination of the Participant’s employment, and (iii) any required salary continuation, notice pay, statutory severance payment or other payments required by local law,
as a result of the Qualifying Termination. The benefits provided under the Plan are intended to satisfy, to the greatest extent possible, and not to provide benefits duplicative of, any and all statutory and contractual obligations of the Company in
respect of the form of benefits provided under the Plan that may arise out of a Qualifying Termination, and the Plan Administrator will so construe and implement the terms of the Plan. Reductions will be applied on a retroactive basis, with benefits
previously provided being recharacterized as benefits pursuant to the Company’s statutory or other contractual obligations. The payments pursuant to the Plan are in addition to, and not in lieu of, any accrued but unpaid salary, bonuses or
employee welfare benefits to which a Participant is entitled for the period ending with the Participant’s Qualifying Termination. 

(c) Mitigation. Except as otherwise specifically provided in the Plan, a Participant will not be required to mitigate damages or the
amount of any payment provided under the Plan by seeking other employment or otherwise, nor will the amount of any payment provided for under the Plan be reduced by any compensation earned by a Participant as a result of employment by another
employer or any retirement benefits received by such Participant after the date of the Participant’s termination of employment with the Company. 

(d) Indebtedness of Participants. If a Participant is indebted to the Company on the effective date of his or her Qualifying
Termination, the Company reserves the right to offset the payment of any benefits under the Plan by the amount of such indebtedness. Such offset will be made in accordance with all applicable laws. The Participant’s execution of the
Participation Notice constitutes knowing written consent to the foregoing. 
 (e) Parachute Payments. Except as otherwise expressly
provided in an agreement between a Participant and the Company, if any payment or benefit the Participant would receive in connection with a Change in Control from the Company or otherwise (a “Payment”) would
(i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise
Tax”), then such Payment will be equal to the Reduced Amount. The “Reduced Amount” will be either (A) the largest portion of the Payment that would result in no portion of the Payment being subject to the
Excise Tax, or (B) the largest portion, up to and including the 

  
 - 6 - 

 
total, of the Payment, whichever amount ((A) or (B)), after taking into account all applicable federal, state, provincial, foreign and local employment taxes, income taxes and the Excise Tax (all
computed at the highest applicable marginal rate), results in the Participant’s receipt, on an after-tax basis, of the greatest economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a
reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, reduction will occur in the following order: (1) reduction of cash payments; (2) cancellation of
accelerated vesting of stock awards other than stock options; (3) cancellation of accelerated vesting of stock options; and (4) reduction of other benefits paid to the Participant. Within any such category of Payments (that is, (1), (2),
(3) or (4)), a reduction will occur first with respect to amounts that are not “deferred compensation” within the meaning of Section 409A and then with respect to amounts that are. In the event that acceleration of vesting of
stock award compensation is to be reduced, such acceleration of vesting will be cancelled in the reverse order of the date of grant of the Participant’s applicable type of stock award (i.e., earliest granted stock awards are cancelled last).

 6. Tax Matters. 
 (a)
Application of Section 409A. It is intended that all of the benefits provided under the Plan satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulations Sections
1.409A-1 (b)(4), 1.409A-1 (b)(5) and 1.409A-1 (b)(9), and the Plan will be construed to the greatest extent possible as consistent with those provisions. To the extent not so exempt, the Plan (and any definitions in the Plan) will be construed in a
manner that complies with Section 409A and incorporates by reference all required definitions and payment terms. For purposes of Section 409A (including, without limitation, for purposes of Treasury Regulations
Section 1.409A-2(b)(2)(iii)), a Participant’s right to receive any installment payments under the Plan will be treated as a right to receive a series of separate payments and, accordingly, each installment payment under the Plan will at
all times be considered a separate and distinct payment. If the Plan Administrator determines that any of the payments upon a Separation from Service provided under the Plan (or under any other arrangement with the Participant) constitutes
“deferred compensation” under Section 409A and if the Participant is a “specified employee” of the Company, as such term is defined in Section 409A(a)(2)(B)(i), at the time of his or her Separation from Service, then,
solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the payments upon a Separation from Service will be delayed as follows: on the earlier to occur of (i) the
date that is six (6) months and one (1) day after the effective date of the Participant’s Separation from Service, or (ii) the date of the Participant’s death (such earlier date, the “Delayed Initial Payment
Date”), the Company will (A) pay to the Participant a lump sum amount equal to the sum of the payments upon Separation from Service that the Participant would otherwise have received through the Delayed Initial Payment Date if the
commencement of the payments had not been delayed pursuant to this paragraph, and (B) commence paying the balance of the payments in accordance with the applicable payment schedules set forth above. No interest will be due on any amounts so
deferred. 
 (b) Withholding. All payments and benefits under the Plan will be subject to all applicable deductions and withholdings,
including, without limitation, obligations to withhold for federal, state, provincial, foreign and local income and employment taxes. 

  
 - 7 - 

 (c) Tax Advice. By becoming a Participant in the Plan, the Participant agrees to review
with the Participant’s own tax advisors the federal, state, provincial, local and foreign tax consequences of participation in the Plan. The Participant will rely solely on such advisors and not on any statements or representations of the
Company or any of its agents. The Participant understands that the Participant (and not the Company) will be responsible for his or her own tax liability that may arise as a result of becoming a Participant in the Plan. 

7. Reemployment. In the event of a Participant’s reemployment by the Company during the period of time in respect of which severance benefits have
been provided, the Company, in its sole and absolute discretion, may require such Participant to repay to the Company all or a portion of such severance benefits as a condition of reemployment. 

8. Clawback; Recovery. All payments and severance benefits provided under the Plan will be subject to recoupment in accordance with any clawback policy
that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and
Consumer Protection Act or other applicable law. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for “good reason,” Constructive Termination or any similar term under any plan of
or agreement with the Company. 
 9. Right to Interpret Plan; Amendment or Termination. 

(a) Exclusive Discretion. The Plan Administrator will have the exclusive discretion and authority to establish rules, forms and
procedures for the administration of the Plan and to construe and interpret the Plan and to decide any and all questions of fact, interpretation, definition, computation or administration arising in connection with the operation of the Plan,
including, without limitation, the eligibility to participate in the Plan, the amount of benefits paid under the Plan and any adjustments that need to be made in accordance with the laws applicable to a Participant. The rules, interpretations,
computations and other actions of the Plan Administrator will be binding and conclusive on all persons. 
 (b) Amendment or
Termination. The Company reserves the right to amend or terminate the Plan, any Participation Notice issued pursuant to the Plan or the benefits provided hereunder at any time; provided, however, that no such amendment or
termination will apply to any Participant who would be adversely affected by such amendment or termination unless such Participant consents in writing to such amendment or termination. Any action amending or terminating the Plan or any Participation
Notice will be in writing and executed by a duly authorized officer of the Company. 
 10. No Implied Employment Contract. The Plan will not be
deemed (a) to give any employee or other person any right to be retained in the employ of the Company, or (b) to interfere with the right of the Company to discharge any employee or other person at any time, with or without cause, which
right is hereby reserved. 

  
 - 8 - 

 11. Legal Construction. The Plan will be governed by and construed under the laws of the State of
California (without regard to principles of conflict of laws), except to the extent preempted by ERISA. 
 12. Claims, Inquiries and Appeals.

 (a) Applications For Benefits And Inquiries. Any application for benefits, inquiries about the Plan or inquiries about present
or future rights under the Plan must be submitted to the Plan Administrator in writing by an applicant (or his or her authorized representative). The Plan Administrator is set forth in Section 14(e). 

(b) Denial of Claims. In the event that any application for benefits is denied in whole or in part, the Plan Administrator must provide
the applicant with written or electronic notice of the denial of the application and of the applicant’s right to review the denial. Any electronic notice will comply with the regulations of the U.S. Department of Labor. The notice of denial
will be set forth in a manner designed to be understood by the applicant and will include the following: 
 (i) the specific reason or
reasons for the denial; 
 (ii) references to the specific Plan provisions upon which the denial is based; 

(iii) a description of any additional information or material that the Plan Administrator needs to complete the review and an explanation of
why such information or material is necessary; and 
 (iv) an explanation of the Plan’s review procedures and the time limits
applicable to such procedures, including a statement of the applicant’s right to bring a civil action under Section 502(a) of ERISA following a denial on review of the claim, as described in Section 12(d). 

The notice of denial will be given to the applicant within ninety (90) days after the Plan Administrator receives the application, unless
special circumstances require an extension of time, in which case, the Plan Administrator has up to an additional ninety (90) days for processing the application. If an extension of time for processing is required, written notice of the
extension will be furnished to the applicant before the end of the initial ninety (90) day period. 
 The notice of extension will
describe the special circumstances necessitating the additional time and the date by which the Plan Administrator is to render its decision on the application. 

(c) Request for a Review. Any person (or that person’s authorized representative) for whom an application for benefits is denied,
in whole or in part, may appeal the denial by submitting a request for a review to the Plan Administrator within sixty (60) days after the application is denied. A request for a review will be in writing and will be addressed to: 

diaDexus, Inc. 
 Attn: Compensation
Committee 
 349 Oyster Point Blvd. 

South San Francisco, CA 94080 

  
 - 9 - 

 A request for review must set forth all of the grounds on which it is based, all facts in support
of the request and any other matters that the applicant feels are pertinent. The applicant (or his or her representative) will have the opportunity to submit (or the Plan Administrator may require the applicant to submit) written comments,
documents, records, and other information relating to his or her claim. The applicant (or his or her representative) will be provided, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information
relevant to his or her claim. The review will take into account all comments, documents, records and other information submitted by the applicant (or his or her representative) relating to the claim, without regard to whether such information was
submitted or considered in the initial benefit determination. 
 (d) Decision on Review. The Plan Administrator will act on each
request for review within sixty (60) days after receipt of the request, unless special circumstances require an extension of time (not to exceed an additional sixty (60) days), for processing the request for a review. If an extension for
review is required, written notice of the extension will be furnished to the applicant within the initial sixty (60) day period. This notice of extension will describe the special circumstances necessitating the additional time and the date by
which the Plan Administrator is to render its decision on the review. The Plan Administrator will give prompt, written or electronic notice of its decision to the applicant. Any electronic notice will comply with the regulations of the U.S.
Department of Labor. In the event that the Plan Administrator confirms the denial of the application for benefits, in whole or in part, the notice will set forth, in a manner designed to be understood by the applicant, the following: 

(i) the specific reason or reasons for the denial; 

(ii) references to the specific Plan provisions upon which the denial is based; 

(iii) a statement that the applicant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all
documents, records and other information relevant to his or her claim; and 
 (iv) a statement of the applicant’s right to bring a
civil action under Section 502(a) of ERISA. 
 (e) Rules and Procedures. The Plan Administrator will establish rules and
procedures, consistent with the Plan and with ERISA, as necessary and appropriate in carrying out its responsibilities in reviewing benefit claims. The Plan Administrator may require an applicant who wishes to submit additional information in
connection with an appeal from the denial of benefits to do so at the applicant’s own expense. 
 (f) Exhaustion Of Remedies. No
legal action for benefits under the Plan may be brought until the applicant (i) has submitted a written application for benefits in accordance with the procedures described by Section 12(a), (ii) has been notified by the Plan
Administrator that the application is denied, (iii) has filed a written request for a review of the application in accordance with the appeal procedure described in Section 12(c), and (iv) has been notified that

  
 - 10 - 

 
the Plan Administrator has denied the appeal. Notwithstanding the foregoing, if the Plan Administrator does not respond to an applicant’s claim or appeal within the relevant time limits
specified in this Section 12, the applicant may bring legal action for benefits under the Plan pursuant to Section 502(a) of ERISA. 
 13.
Basis of Payments to and from the Plan. All benefits under the Plan will be paid by the Company. The Plan will be unfunded, and benefits hereunder will be paid only from the general assets of the Company. 

14. Other Plan Information. 
 (a)
Plan Sponsor. The Company is the “Plan Sponsor,” as that term is used in ERISA. 
 diaDexus, Inc. 

349 Oyster Point Blvd. 
 South San
Francisco, CA 94080 
 (b) Employer and Plan Identification Numbers. The Employer Identification Number assigned to the Plan Sponsor
by the Internal Revenue Service is 94-3236309. The Plan Number assigned to the Plan by the Plan Sponsor pursuant to the instructions of the Internal Revenue Service is 525. 

(c) Ending Date for Plan’s Fiscal Year. The date of the end of the fiscal year for the purpose of maintaining the Plan’s
records is December 31. 
 (d) Agent for the Service of Legal Process. The agent for the service of legal process with respect to the
Plan is: 
 diaDexus, Inc. 

Attn: Chairman of the Compensation Committee 

349 Oyster Point Blvd. 
 South San
Francisco, CA 94080 
 Service of legal process may also be made upon the Plan Administrator. 

(e) Plan Administrator. The Plan Administrator of the Plan is: 

diaDexus, Inc. 
 Attn: Compensation
Committee 
 349 Oyster Point Blvd. 

South San Francisco, CA 94080 
 The Plan
Sponsor’s and Plan Administrator’s telephone number is 650-246-6400. The Plan Administrator is the named fiduciary charged with the responsibility for administering the Plan. 

  
 - 11 - 

 15. Statement of ERISA Rights. 

Participants in the Plan (which is a welfare benefit plan sponsored by diaDexus, Inc.) are entitled to certain rights and protections under
ERISA. If you are a Participant, you are considered a participant in the Plan for the purposes of this Section 15 and, under ERISA, you are entitled to: 

Receive Information About Your Plan and Benefits 

(a) Examine, without charge, at the Plan Administrator’s office and at other specified locations, such as worksites, all documents
governing the Plan and a copy of the latest annual report (Form 5500 Series), if applicable, filed by the Plan with the U.S. Department of Labor and available at the Public Disclosure Room of the Employee Benefits Security Administration; 

(b) Obtain, upon written request to the Plan Administrator, copies of documents governing the operation of the Plan and copies of the latest
annual report (Form 5500 Series), if applicable, and an updated (as necessary) Summary Plan Description. The Plan Administrator may make a reasonable charge for the copies; and 

(c) Receive a summary of the Plan’s annual financial report, if applicable. The Plan Administrator is required by law to furnish each
participant with a copy of this summary annual report. 
 Prudent Actions by Plan Fiduciaries 

In addition to creating rights for Plan participants, ERISA imposes duties upon the people who are responsible for the operation of the
employee benefit plan. The people who operate the Plan, called “fiduciaries” of the Plan, have a duty to do so prudently and in the interest of you and other Plan participants and beneficiaries. No one, including your employer or any other
person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a Plan benefit or exercising your rights under ERISA. 

Enforce Your Rights 
 If
your claim for a Plan benefit is denied or ignored, in whole or in part, you have a right to know why this was done, to obtain copies of documents relating to the decision without charge and to appeal any denial, all within certain time schedules.

 Under ERISA, there are steps you can take to enforce the above rights. For instance, if you request a copy of Plan documents or the
latest annual report from the Plan, if applicable, and do not receive them within thirty (30) days, you may file suit in a federal court. In such a case, the court may require the Plan Administrator to provide the materials and pay you up to
$110 a day until you receive the materials, unless the materials were not sent because of reasons beyond the control of the Plan Administrator. 

If you have a claim for benefits that is denied or ignored, in whole or in part, you may file suit in a state or federal court. 

  
 - 12 - 

 If you are discriminated against for asserting your rights, you may seek assistance from the U.S.
Department of Labor, or you may file suit in a federal court. The court will decide who should pay court costs and legal fees. If you are successful, the court may order the person you have sued to pay these costs and fees. If you lose, the court
may order you to pay these costs and fees, for example, if it finds your claim is frivolous. 
 Assistance with Your Questions 

If you have any questions about the Plan, you should contact the Plan Administrator. If you have any questions about this statement or about
your rights under ERISA, or if you need assistance in obtaining documents from the Plan Administrator, you should contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone
directory or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue N.W., Washington, D.C. 20210. You may also obtain certain publications about your rights
and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration. 
 16. General
Provisions. 
 (a) Plan Document Controls. In the event of any inconsistency between this Plan document and any other
communication regarding this Plan, this Plan document controls. 
 (b) Notices. Any notice, demand or request required or permitted
to be given by either the Company or a Participant pursuant to the terms of the Plan will be in writing and will be deemed given when delivered personally, when received electronically (including email addressed to the Participant’s Company
email account and to the Company email account of the Company’s Chairman of the Compensation Committee), or deposited in the U.S. Mail, First Class with postage prepaid, and addressed to the parties, in the case of the Company, at the address
set forth in Section 14(a), in the case of a Participant, at the address as set forth in the Company’s employment file maintained for the Participant as previously furnished by the Participant or such other address as a party may request
by notifying the other in writing. 
 (c) Transfer and Assignment. The rights and obligations of a Participant under the Plan may not
be transferred or assigned without the prior written consent of the Company. The Plan will be binding upon any surviving entity resulting from a Change in Control and upon any other person who is a successor by merger, acquisition, consolidation or
otherwise to the business formerly carried on by the Company without regard to whether or not such person or entity actively assumes the obligations hereunder. 

(d) Waiver. Any party’s failure to enforce any provision or provisions of the Plan will not in any way be construed as a waiver of
any such provision or provisions, nor prevent any party from thereafter enforcing each and every other provision of the Plan. The rights granted to the parties herein are cumulative and will not constitute a waiver of any party’s right to
assert all other legal remedies available to it under the circumstances. 
 (e) Severability. Should any provision of the Plan be
declared or determined to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions will not in any way be affected or impaired. 

  
 - 13 - 

 (f) Section Headings. Section headings in the Plan are included only for convenience of
reference and will not be considered part of the Plan for any other purpose. 

  
 - 14 - 

 Exhibit A 

DIADEXUS, INC. 
 Key
Employee Severance Benefit Plan 
 Participation Notice 
  

			
	To:	 	  

		
	Date:	 	  

 diaDexus, Inc. (the “Company”) has adopted the diaDexus, Inc. Key Employee Severance
Benefit Plan (the “Plan”). The Company is providing you this Participation Notice to inform you that you have been designated as a Participant in the Plan. A copy of the Plan document is attached to this Participation Notice.
The terms and conditions of your participation in the Plan are as set forth in the Plan and this Participation Notice, which together constitute the Summary Plan Description for the Plan. 

You are a Tier [        ] Participant and so your Severance Period for a Qualifying Termination is
[        ] months. 
 You understand that by accepting your status as a Participant in the Plan, any
of your stock options that have been considered to be “incentive stock options” prior to the date hereof, if applicable, may cease to qualify as “incentive stock options” as a result of the vesting acceleration benefit provided
in the Plan. By accepting participation, you represent that you have either consulted your personal tax or financial planning advisor about the tax consequences of your participation in the Plan, or you have knowingly declined to do so. 

Please return to the Company’s Chief Executive Officer a copy of this Participation Notice signed by you. Please retain a copy of this
Participation Notice, along with the Plan document, for your records. 
  

	
	  

	(Signature)
	
	  

	(Date)

 Exhibit B 

Release Agreement 

[Employees Age 40 or Over; Individual Termination] 

I understand and agree completely to the terms set forth in the diaDexus, Inc. Key Employee Severance Benefit Plan (the
“Plan”). 
 I understand that this Release, together with the Plan, constitutes the complete, final and
exclusive embodiment of the entire agreement between the Company, affiliates of the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company or an affiliate of the Company that is not
expressly stated therein. Certain capitalized terms used in this Release are defined in the Plan. 
 I hereby confirm my obligations under
my Proprietary Information Agreement. 
 Except as otherwise set forth in this Release, I hereby generally and completely release the
Company and its affiliates, and their parents, subsidiaries, successors, predecessors and affiliates, and their partners, members, directors, officers, employees, stockholders, shareholders, agents, attorneys, predecessors, insurers, affiliates and
assigns, from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct or omissions occurring at any time prior to and including the date I sign this Release. This
general release includes, but is not limited to: (a) all claims arising out of or in any way related to my employment with the Company and its affiliates, or their affiliates, or the termination of that employment; (b) all claims related
to my compensation or benefits, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options or any other ownership interests in the Company and its affiliates, or their
affiliates; (c) all claims for breach of contract, wrongful termination and breach of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress and discharge in
violation of public policy; and (e) all federal, state, provincial and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees or other claims arising under the federal Civil Rights Act of 1964
(as amended), the federal Americans with Disabilities Act of 1990 (as amended), the federal Age Discrimination in Employment Act (as amended) (“ADEA”) and the federal Employee Retirement Income Security Act of 1974 (as
amended). 
 Notwithstanding the foregoing, I understand that the following rights or claims are not included in my Release: (a) any
rights or claims for indemnification I may have pursuant to any written indemnification agreement with the Company or its affiliate to which I am a party; the charter, bylaws or operating agreements of the Company or its affiliate; or under
applicable law; or (b) any rights which cannot be waived as a matter of law. In addition, I understand that nothing in this Release prevents me from filing, cooperating with or participating in any proceeding before the Equal Employment
Opportunity Commission or the U.S. Department of Labor, except that I hereby waive my right to any monetary benefits in connection with any such claim, charge or proceeding. 

I hereby represent and warrant that, other than the claims identified in this paragraph, I am not aware of any claims I have or might have
that are not included in the Release. 

 I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have
under the ADEA, and that the consideration given under the Plan for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this
writing, as required by the ADEA, that: (a) my waiver and release do not apply to any rights or claims that may arise after the date I sign this Release; (b) I should consult with an attorney prior to signing this Release (although I may
choose voluntarily not do so); (c) I have twenty-one (21) days to consider this Release (although I may choose voluntarily to sign this Release earlier); (d) I have seven (7) days following the date I sign this Release to revoke
the Release by providing written notice to an officer of the Company; and (e) this Release will not be effective until the date upon which the revocation period has expired, which will be the eighth (8th) day after I sign this Release.

 I hereby represent that I have been paid all compensation owed and for all hours worked; I have received all the leave and leave benefits
and protections for which I am eligible pursuant to the Family and Medical Leave Act, or otherwise; and I have not suffered any on-the-job injury for which I have not already filed a workers’ compensation claim. 

I acknowledge that to become effective, I must sign and return this Release to the Company so that it is received not later than twenty-one
(21) days following the date it is provided to me. 
  

			
	PARTICIPANT:
	
	  

	(Signature)
		
	By:	 	  

	Date:	 	  

 Exhibit C 

Release Agreement 

[Employees Age 40 or Over; Group Termination] 

I understand and agree completely to the terms set forth in the diaDexus, Inc. Key Employee Severance Benefit Plan (the
“Plan”). 
 I understand that this Release, together with the Plan, constitutes the complete, final and
exclusive embodiment of the entire agreement between the Company, affiliates of the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company or an affiliate of the Company that is not
expressly stated therein. Certain capitalized terms used in this Release are defined in the Plan. 
 I hereby confirm my obligations under
my Proprietary Information Agreement. 
 Except as otherwise set forth in this Release, I hereby generally and completely release the
Company and its affiliates, and their parents, subsidiaries, successors, predecessors and affiliates, and its and their partners, members, directors, officers, employees, stockholders, shareholders, agents, attorneys, predecessors, insurers,
affiliates and assigns, from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct or omissions occurring at any time prior to and including the date I sign this
Release. This general release includes, but is not limited to: (a) all claims arising out of or in any way related to my employment with the Company and its affiliates, or their affiliates, or the termination of that employment; (b) all
claims related to my compensation or benefits, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options or any other ownership interests in the Company and its affiliates, or
their affiliates; (c) all claims for breach of contract, wrongful termination and breach of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress and discharge
in violation of public policy; and (e) all federal, state, provincial and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees or other claims arising under the federal Civil Rights Act of
1964 (as amended), the federal Americans with Disabilities Act of 1990 (as amended), the federal Age Discrimination in Employment Act (as amended) (“ADEA”) or the federal Employee Retirement Income Security Act of 1974 (as
amended). 
 Notwithstanding the foregoing, I understand that the following rights or claims are not included in my Release: (a) any
rights or claims for indemnification I may have pursuant to any written indemnification agreement with the Company or its affiliate to which I am a party; the charter, bylaws or operating agreements of the Company or its affiliate; or under
applicable law; or (b) any rights which cannot be waived as a matter of law. In addition, I understand that nothing in this Release prevents me from filing, cooperating with or participating in any proceeding before the Equal Employment
Opportunity Commission, or the U.S. Department of Labor, except that I hereby waive my right to any monetary benefits in connection with any such claim, charge or proceeding. I hereby represent and warrant that, other than the claims identified in
this paragraph, I am not aware of any claims I have or might have that are not included in the Release. 

 I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have
under the ADEA, and that the consideration given under the Plan for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this
writing, as required by the ADEA, that: (a) my waiver and release do not apply to any rights or claims that may arise after the date I sign this Release; (b) I should consult with an attorney prior to signing this Release (although I may
choose voluntarily not to do so); (c) I have forty-five (45) days to consider this Release (although I may choose voluntarily to sign this Release earlier); (d) I have seven (7) days following the date I sign this Release to
revoke the Release by providing written notice to an office of the Company; (e) this Release will not be effective until the date upon which the revocation period has expired, which will be the eighth (8th) day after I sign this Release;
and (f) I have received with this Release a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational
unit who were not terminated. 
 I hereby represent that I have been paid all compensation owed and for all hours worked; I have received
all the leave and leave benefits and protections for which I am eligible pursuant to the Family and Medical Leave Act, or otherwise; and I have not suffered any on-the-job injury for which I have not already filed a workers’ compensation claim.

 I acknowledge that to become effective, I must sign and return this Release to the Company so that it is received not later than
forty-five (45) days following the date it is provided to me. 
  

			
	PARTICIPANT:
	
	  

	(Signature)
		
	By:	 	  

	Date:	 	  

 Exhibit D 

Release Agreement 

[Employees Under Age 40] 

I understand and agree completely to the terms set forth in the diaDexus, Inc. Key Employee Severance Benefit Plan (the
“Plan”). 
 I understand that this Release, together with the Plan, constitutes the complete, final and
exclusive embodiment of the entire agreement between the Company, affiliates of the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company or an affiliate of the Company that is not
expressly stated therein. Certain capitalized terms used in this Release are defined in the Plan. 
 I hereby confirm my obligations under
my Proprietary Information Agreement. 
 Except as otherwise set forth in this Release, I hereby generally and completely release the
Company and its affiliates, and their parents, subsidiaries, successors, predecessors and affiliates, and its and their partners, members, directors, officers, employees, stockholders, shareholders, agents, attorneys, predecessors, insurers,
affiliates and assigns, from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct or omissions occurring at any time prior to and including the date I sign this
Release. This general release includes, but is not limited to: (a) all claims arising out of or in any way related to my employment with the Company and its affiliates, or their affiliates, or the termination of that employment; (b) all
claims related to my compensation or benefits, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options or any other ownership interests in the Company and its affiliates, or
their affiliates; (c) all claims for breach of contract, wrongful termination and breach of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress and discharge
in violation of public policy; and (e) all federal, state, provincial and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees or other claims arising under the federal Civil Rights Act of
1964 (as amended), the federal Americans with Disabilities Act of 1990 (as amended) or the federal Employee Retirement Income Security Act of 1974 (as amended). 

Notwithstanding the foregoing, I understand that the following rights or claims are not included in my Release: (a) any rights or claims
for indemnification I may have pursuant to any written indemnification agreement with the Company or its affiliate to which I am a party; the charter, bylaws or operating agreements of the Company or its affiliate; or under applicable law; or
(b) any rights which cannot be waived as a matter of law. In addition, I understand that nothing in this Release prevents me from filing, cooperating with or participating in any proceeding before the Equal Employment Opportunity Commission, or
the U.S. Department of Labor, except that I hereby waive my right to any monetary benefits in connection with any such claim, charge or proceeding. I hereby represent and warrant that, other than the claims identified in this paragraph, I am not
aware of any claims I have or might have that are not included in the Release. 

 I hereby represent that I have been paid all compensation owed and for all hours worked; I have
received all the leave and leave benefits and protections for which I am eligible pursuant to the Family and Medical Leave Act, or otherwise; and I have not suffered any on-the-job injury for which I have not already filed a workers’
compensation claim. 
 I acknowledge that to become effective, I must sign and return this Release to the Company so that it is received not
later than fourteen (14) days following the date it is provided to me. 
  

			
	PARTICIPANT:
	
	  

	(Signature)
		
	By:	 	  

	Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]